Pfizer

December 18, 2019December 18, 2019

FDA Approves Extended-Release Xeljanz for Adults with Ulcerative Colitis

News

The U.S. Food and Drug Administration (FDA) has approved Pfizer‘s extended-release tablets of Xeljanz XR (tofacitinib) to treat adults with moderately to severely active ulcerative colitis. This approval of 11 mg ... Read more

November 22, 2019November 22, 2019

FDA Approves Pfizer’s Abrilada, Biosimilar to Humira, for IBD and Other Inflammatory Disorders

News

Abrilada (adalimumab-afzb), a biosimilar to Humira (adalimumab), has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of seven inflammatory disorders, including adult Crohn’s disease and ... Read more

August 26, 2019August 26, 2019

Safety Concerns Prompt Prescription Changes Among Gastroenterologists

News

A survey of gastroenterologists in the United States shows that data from the VARSITY clinical trial, as well as safety concerns about the experimental treatment Xeljanz, are affecting how some ... Read more

March 20, 2019March 20, 2019

Newly Funded Projects Aim to Improve Vaccine Use, Preventive Care in IBD

News

Some $1 million in funding will go to three projects aimed at addressing gaps in vaccine use and communication among healthcare providers and patients with inflammatory bowel disease (IBD). Made ... Read more

November 28, 2018November 28, 2018

Cosentyx May Increase Risk for Inflammatory Bowel Disease, Italian Researchers Say

News

Italian researchers are calling attention to what they say is an alarming number of newly diagnosed cases of inflammatory bowel disease (IBD) in people treated with the human monoclonal antibody ... Read more

August 3, 2018August 3, 2018

Pfizer’s Xeljanz Approved in EU for Adults with Moderate to Severe Ulcerative Colitis

News, Ulcerative colitis

The European Commission has approved Pfizer‘s Xeljanz (tofacitinib) for the treatment of adults with moderate to severe active ulcerative colitis (UC) who have failed to fully respond to other therapies. The ... Read more

June 1, 2018June 1, 2018

FDA Approves Pfizer’s Xeljanz, an Oral Twice Daily Treatment for Adults with Moderate to Severe Ulcerative Colitis

News

The U.S. Food and Drug Administration (FDA) has approved the oral therapy Xeljanz (tofacitinib), by Pfizer, to treat adults with moderately to severely active ulcerative colitis (UC), the company announced. The treatment regimen calls ... Read more

May 23, 2018May 23, 2018

Projects Aim to Improve Decision-making, Communication Between IBD Patients, MDs

News

The Crohn’s and Colitis Foundation, the American Gastroenterological Association (AGA) and Pfizer recently presented the results of a request for proposals to devise interventions aimed at improving shared decision-making and ... Read more

March 12, 2018March 12, 2018

FDA Advisory Panel Favors Extended Use of Xeljanz by Certain Ulcerative Colitis Patients

News

An advisory arm of the U.S. Food and Drug Administration (FDA) gave two positive recommendations to Pfizer’s supplemental New Drug Application, seeking FDA approval for extended use of Xeljanz (tofacitinib) by certain adult ... Read more

January 24, 2018

U.S. Survey Sheds Light on How Ulcerative Colitis Affects Patients’ Lives

News

Two-thirds of ulcerative colitis patients believe the disease affects their personal relationships and half think it impacts their ability to obtain an education or their career, a U.S. survey shows. The UC ... Read more